AMRX
Amneal Pharmaceuticals, Inc.
$16.20
-0.86%
$5.2B
No data for this timeframe.
Vol
Market Cap$5.2B
Cap SizeMid Cap
Analyst ConsensusStrong Buy (91%)
Inst. Holders50 funds
Inst. Value$1.4B
Inst. Activity25 buys / 12 sells
Insider Activity0B / 1S
Insider Net $-$450.6K
Reddit Sentiment33° Cool
SEC Reports6
Recent Activity
Jun 12, 2026
short_volume
Short Volume: AMRX — 60.1% short (0.5M / 0.9M)
Short: 546,584 | Exempt: 0 | TRF Vol: 909,077 | Short Ratio: 60.1% | Off-exchange volume (dark pool
Jun 11, 2026
SEC
Two mega-passives (Morgan Stanley, Invesco) and two quants (D.E. Shaw, Two Sigma) added $31M in AMRX during Q3, while tw
INST-CLUSTER — Impact 4/10
May 29, 2026
Event
Warfarin Sodium
WARNING: BLEEDING RISK Warfarin sodium can cause major or fatal bleeding [see Warnings and Precautio
May 11, 2026
Insider
Autor Deborah M. sold 34,819 shares
Director @ $12.94 ($450.6K)
May 7, 2026
SEC
Amneal Pharmaceuticals reported Q1 2026 adjusted EPS of $0.27, beating consensus of $0.17 by 58.8%, and revenue of $723M
PRESS-RELEASE — Impact 8/10
May 7, 2026
Insider
Yanai Shlomo acquired via exercise 34,819 shares
Director
May 7, 2026
Insider
MEISTER PAUL M acquired via exercise 48,747 shares
Director
Apr 22, 2026
SEC
Amneal Pharmaceuticals reported strong preliminary Q1 2026 results with revenue of $723M (4% YoY growth) and adjusted di
PRESS-RELEASE — Impact 9/10
Price Targets
$17.25
+6.5% upside
Buy
Current $16.20
Low $16.00
Median $17.00
High $19.00
4 analysts
$16.00
$19.00
Analyst Ratings
2Strong Buy
8Buy
1Hold
0Sell
0Strong Sell
Recent Analyst Actions
| Date | Firm | Action | Rating |
|---|---|---|---|
| May 20, 2026 | Barclays | MAINTAIN | Overweight → Overweight |
| Apr 17, 2026 | UBS | INITIATE | Buy |
| Mar 2, 2026 | Truist Securities | MAINTAIN | Buy → Buy |
Earnings Estimates
| Period | EPS Est. | Range | Growth | # |
|---|---|---|---|---|
| Current Q | $0.23 | $0.21 — $0.26 | -7% YoY | 5 |
| Next Q | $0.25 ▼ -10.8% | $0.22 — $0.28 | 46% YoY | 5 |
| Current FY | $0.99 ▼ -1.0% | $0.94 — $1.01 | 19% YoY | 5 |
| Next FY | $1.12 ▼ -5.1% | $1.04 — $1.20 | 14% YoY | 5 |
Latest Reports
MIXED
INST-CLUSTER
4/10
Two mega-passives (Morgan Stanley, Invesco) and two quants (D.E. Shaw, Two Sigma) added $31M in AMRX during Q3, while tw
Jun 11, 2026
BULLISH
PRESS-RELEASE
8/10
Amneal Pharmaceuticals reported Q1 2026 adjusted EPS of $0.27, beating consensus of $0.17 by 58.8%, and revenue of $723M
May 7, 2026
Top Institutional Holders
| Fund | Value | Move |
|---|---|---|
| BlackRock, Inc. | $304.8M | ADD |
| VANGUARD PORTFOLIO MANAGEMENT LLC | $140.8M | — |
| Rubric Capital Management LP | $137.2M | — |
| VANGUARD CAPITAL MANAGEMENT LLC | $94.3M | — |
| STATE STREET CORP | $84.5M | ADD |
Recent Insider Trades
| Date | Insider | Type | Value |
|---|---|---|---|
| May 11, 2026 | Autor Deborah | SELL | $450.6K |
| May 7, 2026 | Yanai Shlomo | M | $0.00 |
| May 7, 2026 | MEISTER PAUL | M | $0.00 |
| May 7, 2026 | Nark Ted | M | $0.00 |
| May 7, 2026 | Kiely John | M | $0.00 |
Reddit Sentiment
33°
Cool
Bearish
Neutral
Bullish
50 institutional holders with $1.4B total value (108,985,646 shares) as of 2026-Q1. Top holders: BlackRock,, VANGUARD, Rubric. Net buying activity: 25 institutions added/increased vs 12 reduced.
Top Institutional Holders — 2026-Q1
| # | Fund | Shares | Value | % of Tracked | Last Move |
|---|---|---|---|---|---|
| 1 | BlackRock, Inc. | 24,519,192 | $304.8M | 22.5% | ADD +71.5% |
| 2 | VANGUARD PORTFOLIO MANAGEMENT LLC | 11,324,933 | $140.8M | 10.4% | — |
| 3 | Rubric Capital Management LP | 11,037,589 | $137.2M | 10.1% | — |
| 4 | VANGUARD CAPITAL MANAGEMENT LLC | 7,585,034 | $94.3M | 7.0% | — |
| 5 | STATE STREET CORP | 6,794,702 | $84.5M | 6.2% | ADD +65.3% |
| 6 | DIMENSIONAL FUND ADVISORS LP | 5,690,586 | $70.7M | 5.2% | — |
| 7 | MORGAN STANLEY | 4,637,185 | $57.6M | 4.3% | ADD +37.5% |
| 8 | Neuberger Berman Group LLC | 3,682,284 | $45.7M | 3.4% | — |
| 9 | Nuveen, LLC | 3,243,643 | $40.3M | 3.0% | — |
| 10 | Invesco Ltd. | 3,188,659 | $39.6M | 2.9% | ADD +82.1% |
| 11 | Assenagon Asset Management S.A. | 3,067,361 | $38.1M | 2.8% | ADD +75.0% |
| 12 | GOLDMAN SACHS GROUP INC | 2,863,860 | $35.6M | 2.6% | — |
| 13 | Allspring Global Investments Holdings, LLC | 2,549,572 | $32.4M | 2.4% | ADD +72.2% |
| 14 | CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 2,184,161 | $27.1M | 2.0% | — |
| 15 | AMERIPRISE FINANCIAL INC | 1,865,201 | $23.2M | 1.7% | ADD +45.3% |
| 16 | D. E. Shaw & Co., Inc. | 1,719,954 | $21.4M | 1.6% | ADD +70.1% |
| 17 | VANGUARD FIDUCIARY TRUST CO | 1,154,023 | $14.3M | 1.1% | — |
| 18 | FMR LLC | 792,010 | $9.8M | 0.7% | ADD +28.4% |
| 19 | FIRST TRUST ADVISORS LP | 757,157 | $9.4M | 0.7% | — |
| 20 | RAYMOND JAMES FINANCIAL INC | 734,043 | $9.1M | 0.7% | — |
Recent Position Changes
| Fund | Action | Prev Shares | Curr Shares | Change % | Value | Quarter |
|---|---|---|---|---|---|---|
| BlackRock, Inc. | ADD | 14,298,520 | 24,519,192 | +71.5% | $304.8M | 2026-Q1 |
| STATE STREET CORP | ADD | 4,110,410 | 6,794,702 | +65.3% | $84.5M | 2026-Q1 |
| Invesco Ltd. | ADD | 1,750,718 | 3,188,659 | +82.1% | $39.6M | 2026-Q1 |
| Allspring Global Investments Holdings, LLC | ADD | 1,480,172 | 2,549,572 | +72.2% | $32.4M | 2026-Q1 |
| AMERIPRISE FINANCIAL INC | ADD | 1,283,256 | 1,865,201 | +45.3% | $23.2M | 2026-Q1 |
| SEI INVESTMENTS CO | ADD | 559,432 | 706,681 | +26.3% | $8.8M | 2026-Q1 |
| BANK OF AMERICA CORP /DE/ | ADD | 451,158 | 676,795 | +50.0% | $8.4M | 2026-Q1 |
| ARROWSTREET CAPITAL, LIMITED PARTNERSHIP | TRIM | 1,090,424 | 523,967 | -51.9% | $6.5M | 2026-Q1 |
| PRUDENTIAL FINANCIAL INC | ADD | 406,140 | 511,957 | +26.1% | $6.4M | 2026-Q1 |
| VICTORY CAPITAL MANAGEMENT INC | DOUBLED | 18,051 | 461,974 | +2459.3% | $5.7M | 2026-Q1 |
| Legal & General Group Plc | DOUBLED | 149,304 | 364,530 | +144.2% | $4.5M | 2026-Q1 |
| RHUMBLINE ADVISERS | ADD | 200,750 | 363,502 | +81.1% | $4.5M | 2026-Q1 |
| ENVESTNET ASSET MANAGEMENT INC | ADD | 235,315 | 314,273 | +33.6% | $3.9M | 2026-Q1 |
| RENAISSANCE TECHNOLOGIES LLC | DOUBLED | 16,400 | 276,637 | +1586.8% | $3.4M | 2026-Q1 |
| HEALTHCARE OF ONTARIO PENSION PLAN TRUST FUND | ADD | 131,600 | 254,373 | +93.3% | $3.2M | 2026-Q1 |
| VOLORIDGE INVESTMENT MANAGEMENT, LLC | TRIM | 563,680 | 204,883 | -63.7% | $2.5M | 2026-Q1 |
| Artemis Investment Management LLP | ADD | 124,899 | 186,125 | +49.0% | $2.3M | 2026-Q1 |
| ExodusPoint Capital Management, LP | NEAR_EXIT | 825,999 | 161,700 | -80.4% | $2.0M | 2026-Q1 |
| Brevan Howard Capital Management LP | DOUBLED | 70,085 | 143,997 | +105.5% | $1.8M | 2026-Q1 |
| MASSACHUSETTS FINANCIAL SERVICES CO /MA/ | TRIM | 175,377 | 127,087 | -27.5% | $1.6M | 2026-Q1 |
| JENNISON ASSOCIATES LLC | ADD | 77,401 | 124,898 | +61.4% | $1.6M | 2026-Q1 |
| Magnetar Financial LLC | DOUBLED | 10,202 | 81,001 | +694.0% | $1.0M | 2026-Q1 |
| BALYASNY ASSET MANAGEMENT L.P. | NEAR_EXIT | 689,867 | 79,123 | -88.5% | $983.5K | 2026-Q1 |
| Concurrent Investment Advisors, LLC | TRIM | 81,966 | 59,634 | -27.2% | $741.3K | 2026-Q1 |
| Rockefeller Capital Management L.P. | TRIM | 109,959 | 32,970 | -70.0% | $409.8K | 2026-Q1 |
14 unique insiders with 50 transactions. Net insider value: -$450.6K ($0.00 bought, $450.6K sold).
Insider Transactions
| Date | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| May 11, 2026 | Autor Deborah M. | Director | SELL | 34,819 | $12.94 | $450.6K |
| May 7, 2026 | Yanai Shlomo | Director | EXERCISE | 34,819 | — | — |
| May 7, 2026 | MEISTER PAUL M | Director | EXERCISE | 48,747 | — | — |
| May 7, 2026 | Nark Ted C | Director | EXERCISE | 34,819 | — | — |
| May 7, 2026 | Kiely John | Director | EXERCISE | 34,819 | — | — |
| May 7, 2026 | Patel Gautam | Director | EXERCISE | 34,819 | — | — |
| May 7, 2026 | George Jeffrey P. | Director | EXERCISE | 34,819 | — | — |
| May 7, 2026 | Autor Deborah M. | Director | EXERCISE | 34,819 | — | — |
| May 7, 2026 | BUCHI J KEVIN | Director | EXERCISE | 34,819 | — | — |
| May 6, 2026 | BUCHI J KEVIN | Director | AWARD | 19,824 | — | — |
| May 6, 2026 | Autor Deborah M. | Director | AWARD | 19,824 | — | — |
| May 6, 2026 | George Jeffrey P. | Director | AWARD | 19,824 | — | — |
| May 6, 2026 | Patel Gautam | Director | AWARD | 19,824 | — | — |
| May 6, 2026 | Kiely John | Director | AWARD | 19,824 | — | — |
| May 6, 2026 | Nark Ted C | Director | AWARD | 19,824 | — | — |
| May 6, 2026 | MEISTER PAUL M | Director | AWARD | 30,837 | — | — |
| May 6, 2026 | Yanai Shlomo | Director | AWARD | 19,824 | — | — |
| Mar 4, 2026 | Patel Chintu | Co-CEO | EXERCISE | 92,593 | — | — |
| Mar 4, 2026 | Patel Chirag K. | President & Co-CEO | EXERCISE | 92,593 | — | — |
| Mar 4, 2026 | Daly Jason B. | EVP, Chief Legal Officer | EXERCISE | 35,880 | — | — |
| Mar 4, 2026 | Konidaris Tasos | Executive Vice President & CFO | EXERCISE | 43,982 | — | — |
| Mar 4, 2026 | Konidaris Tasos | Executive Vice President & CFO | EXERCISE | 49,982 | — | — |
| Mar 4, 2026 | BOYER ANDREW S | Executive Vice President | EXERCISE | 38,195 | — | — |
| Mar 4, 2026 | Shah Nikita | Executive Vice President | EXERCISE | 35,880 | — | — |
| Mar 3, 2026 | Patel Chintu | Co-CEO | EXERCISE | 59,931 | — | — |
| Mar 3, 2026 | Patel Chintu | Co-CEO | EXERCISE | 733,944 | — | — |
| Mar 3, 2026 | Patel Chirag K. | President & Co-CEO | EXERCISE | 733,944 | — | — |
| Mar 3, 2026 | Daly Jason B. | EVP, Chief Legal Officer | EXERCISE | 22,645 | — | — |
| Mar 3, 2026 | Daly Jason B. | EVP, Chief Legal Officer | EXERCISE | 305,810 | — | — |
| Mar 3, 2026 | Konidaris Tasos | Executive Vice President & CFO | EXERCISE | 458,716 | — | — |
| Mar 3, 2026 | BOYER ANDREW S | Executive Vice President | EXERCISE | 397,554 | — | — |
| Mar 3, 2026 | Shah Nikita | Executive Vice President | EXERCISE | 366,972 | — | — |
| Mar 3, 2026 | Patel Chirag K. | President & Co-CEO | EXERCISE | 59,931 | — | — |
| Mar 3, 2026 | Konidaris Tasos | Executive Vice President & CFO | EXERCISE | 45,290 | — | — |
| Mar 3, 2026 | BOYER ANDREW S | Executive Vice President | EXERCISE | 39,252 | — | — |
| Mar 3, 2026 | Shah Nikita | Executive Vice President | EXERCISE | 36,232 | — | — |
| Mar 2, 2026 | Patel Chirag K. | President & Co-CEO | AWARD | 544,663 | — | — |
| Mar 2, 2026 | Patel Chintu | Co-CEO | AWARD | 544,663 | — | — |
| Mar 2, 2026 | Daly Jason B. | EVP, Chief Legal Officer | AWARD | 65,359 | — | — |
| Mar 2, 2026 | Daly Jason B. | EVP, Chief Legal Officer | AWARD | 65,359 | — | — |
| Mar 2, 2026 | Konidaris Tasos | Executive Vice President & CFO | AWARD | 72,622 | — | — |
| Mar 2, 2026 | Konidaris Tasos | Executive Vice President & CFO | AWARD | 72,622 | — | — |
| Mar 2, 2026 | Patel Chintu | Co-CEO | AWARD | 190,632 | — | — |
| Mar 2, 2026 | Patel Chintu | Co-CEO | AWARD | 354,031 | — | — |
| Mar 2, 2026 | Patel Chirag K. | President & Co-CEO | AWARD | 190,632 | — | — |
| Mar 2, 2026 | Patel Chirag K. | President & Co-CEO | AWARD | 354,031 | — | — |
| Mar 2, 2026 | Shah Nikita | Executive Vice President | AWARD | 65,359 | — | — |
| Mar 2, 2026 | Shah Nikita | Executive Vice President | AWARD | 65,359 | — | — |
| Mar 2, 2026 | BOYER ANDREW S | Executive Vice President | AWARD | 65,359 | — | — |
| Mar 2, 2026 | BOYER ANDREW S | Executive Vice President | AWARD | 65,359 | — | — |
6 SEC filing reports analyzed. Sentiment: 3 bullish, 0 bearish, 1 mixed, 2 neutral. Avg impact: 5.8/10.
MIXED
INST-CLUSTER
4/10
Two mega-passives (Morgan Stanley, Invesco) and two quants (D.E. Shaw, Two Sigma) added $31M in AMRX
Jun 11, 2026
BULLISH
PRESS-RELEASE
8/10
Amneal Pharmaceuticals reported Q1 2026 adjusted EPS of $0.27, beating consensus of $0.17 by 58.8%,
May 7, 2026
BULLISH
PRESS-RELEASE
9/10
Amneal Pharmaceuticals reported strong preliminary Q1 2026 results with revenue of $723M (4% YoY gro
Apr 22, 2026
NEUTRAL
PRESS-RELEASE
3/10
Amneal Pharmaceuticals announced it will release Q1 2026 financial results on May 1, 2026, with no u
Apr 7, 2026
NEUTRAL
DEFA14A
3/10
Amneal Pharmaceuticals, Inc. (AMRX) has filed a definitive proxy statement (DEFA14A) related to a sh
Mar 25, 2026
BULLISH
8-K
8/10
Amneal Pharmaceuticals reported strong Q4 and full-year 2025 results, with revenue up 11% and 8% YoY
Feb 27, 2026
No press releases analyzed yet. Press releases are collected from GlobeNewsWire and analyzed by the LLM pipeline.
Current analyst consensus: Strong Buy (91% buy). Based on 11 analysts: 2 strong buy, 8 buy, 1 hold, 0 sell, 0 strong sell.
Analyst Price Targets
$17.25 mean target
+6.5% upside
Buy (1.50)
$16.00 Low
$19.00 High
| Metric | Value |
|---|---|
| Current Price | $16.20 |
| Target Low | $16.00 |
| Target Mean | $17.25 |
| Target Median | $17.00 |
| Target High | $19.00 |
| # Analysts | 4 |
| Recommendation | Buy (1.50) |
Earnings Estimates & Revisions
| Period | EPS Avg | EPS Low | EPS High | EPS Growth | 30d Rev. | Up/Down | Rev. Avg | Rev. Growth | Analysts |
|---|---|---|---|---|---|---|---|---|---|
| Current Q 2026-06-30 |
$0.23 | $0.21 | $0.26 | -7.2% | +0.2% | 2↑ 1↓ | $0.8B | 5.6% | 5 |
| Next Q 2026-09-30 |
$0.25 | $0.22 | $0.28 | 46.1% | -10.8% | 0↑ 3↓ | $0.8B | 3.6% | 5 |
| Current FY 2026-12-31 |
$0.99 | $0.94 | $1.01 | 18.9% | -1.0% | 2↑ 1↓ | $3.1B | 2.9% | 5 |
| Next FY 2027-12-31 |
$1.12 | $1.04 | $1.20 | 13.8% | -5.1% | 0↑ 3↓ | $3.3B | 7.2% | 5 |
Current Quarter EPS Revision History
| Timepoint | EPS Estimate | Change |
|---|---|---|
| Current | $0.232 | |
| 7d ago | $0.233 | -0.001 |
| 30d ago | $0.232 | +0.001 |
| 60d ago | $0.234 | -0.002 |
| 90d ago | $0.230 | +0.002 |
3 analyst firms have rated this stock: 0 upgrades, 0 downgrades, 1 initiations.
Individual Analyst Actions
| Date | Analyst Firm | Action | Previous Rating | New Rating |
|---|---|---|---|---|
| May 20, 2026 | Barclays | MAINTAIN | Overweight | Overweight |
| Apr 17, 2026 | UBS | INITIATE | — | Buy |
| Mar 2, 2026 | Truist Securities | MAINTAIN | Buy | Buy |
Monthly Consensus History
| Period | Strong Buy | Buy | Hold | Sell | Strong Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| Jun 1, 2026 | 2 | 8 | 1 | 0 | 0 | 91% | |
| May 1, 2026 | 2 | 8 | 1 | 0 | 0 | 91% | |
| Apr 1, 2026 | 2 | 8 | 1 | 0 | 0 | 91% | |
| Mar 1, 2026 | 2 | 8 | 1 | 0 | 0 | 91% | |
| Feb 1, 2026 | 2 | 8 | 1 | 0 | 0 | 91% | |
| Jan 1, 2026 | 2 | 8 | 1 | 0 | 0 | 91% |
Strong BuyBuyHoldSellStrong Sell
No congressional trading data available for this ticker. Data is sourced from Senate and House financial disclosure filings.
33°
Cool
Bearish
Neutral
Bullish
2 mentions
0 bullish
2 bearish
2 time periods
Reddit Sentiment History
| Date | Mentions | Sentiment | Bullish | Bearish | Threads |
|---|---|---|---|---|---|
| Mar 6, 2026 | 1 | 40° Cool | 0 | 1 | 1 |
| Mar 6, 2026 | 1 | 40° Cool | 0 | 1 | 1 |
Recent Reddit Threads
Jun 12, 2026
short_volume
Short Volume: AMRX — 60.1% short (0.5M / 0.9M)
Short: 546,584 | Exempt: 0 | TRF Vol: 909,077 | Short Ratio: 60.1% | Off-exchange volume (dark pool + OTC)
Jun 5, 2026
other
Amneal Announces Full Study Population Interim Phase 4 ELEVATE-PD Results, Reinforcing Previously Reported Benefits of CREXONT® in Parkinson's Disease
<p align="left">BRIDGEWATER, N.J., June 05, 2026 (GLOBE NEWSWIRE) -- Amneal Pharmaceuticals, Inc. (Nasdaq: AMRX) (“Amneal” or the “Company”), today
May 29, 2026
short_volume
Short Volume: AMRX — 69.8% short (0.4M / 0.6M)
Short: 431,247 | Exempt: 0 | TRF Vol: 617,788 | Short Ratio: 69.8% | Off-exchange volume (dark pool + OTC)
May 29, 2026
FDA
Warfarin Sodium
WARNING: BLEEDING RISK Warfarin sodium can cause major or fatal bleeding [see Warnings and Precautions (5.1) ] . Perform regular monitoring of INR in
May 15, 2026
FDA
OXYCODONE HYDROCHLORIDE
WARNING: ADDICTION, ABUSE AND MISUSE; RISK EVALUATION AND MITIGATION STRATEGY (REMS); LIFE-THREATENING RESPIRATORY DEPRESSION; ACCIDENTAL INGESTION; N
May 14, 2026
short_volume
Short Volume: AMRX — 58.3% short (0.3M / 0.6M)
Short: 320,793 | Exempt: 422 | TRF Vol: 550,169 | Short Ratio: 58.3% | Off-exchange volume (dark pool + OTC)
May 13, 2026
FDA
Pyridostigmine bromide
WARNING: RISKS WITH IMPROPER USE OF PYRIDOSTIGMINE BROMIDE After Exposure to Soman, Use Atropine and Pralidoxime Pyridostigmine bromide is for use as
May 12, 2026
FDA
PYRIDOSTIGMINE BROMIDE
Supplemental Approval — Labeling — TABLET, EXTENDED RELEASE
May 7, 2026
earnings
Amneal Reports First Quarter 2026 Financial Results
<p align="center"><em>‒ </em><em>Q1 2026</em><em> Net Revenue of </em><em>$723 million</em><em>; GAAP Net </em><em>Income</em><em> of </em><em>$62 mil
May 1, 2026
earnings_calendar
AMRX Q1 2026 Earnings Scheduled — 2026-05-01
Apr 22, 2026
earnings
Amneal Agrees to Acquire Kashiv BioSciences to Create Global Biosimilar Leader; Reports Strong Preliminary First Quarter 2026 Financial Results and Raises FY2026 Standalone Guidance
<p align="center"><em>– Acquisition Positions Amneal to Capitalize on $300B+ Global Biologics LOE Opportunity –</em></p>
Apr 22, 2026
short_volume
Short Volume: AMRX — 78.4% short (0.9M / 1.1M)
Short: 858,631 | Exempt: 35 | TRF Vol: 1,095,807 | Short Ratio: 78.4% | Off-exchange volume (dark pool + OTC)
Apr 17, 2026
short_volume
Short Volume: AMRX — 69.4% short (0.4M / 0.5M)
Short: 379,870 | Exempt: 560 | TRF Vol: 547,170 | Short Ratio: 69.4% | Off-exchange volume (dark pool + OTC)
Apr 14, 2026
other
Amneal Launches First Two Respiratory Metered-Dose Inhalation Products in the U.S.
<p>BRIDGEWATER, N.J., April 14, 2026 (GLOBE NEWSWIRE) -- Amneal Pharmaceuticals, Inc. (“Amneal” or the “Company”) (Nasdaq: AMRX) today announced the
Apr 10, 2026
short_volume
Short Volume: AMRX — 73.6% short (0.4M / 0.6M)
Short: 408,334 | Exempt: 0 | TRF Vol: 554,576 | Short Ratio: 73.6% | Off-exchange volume (dark pool + OTC)
Apr 8, 2026
FDA
traMADol Hydrochloride Tablets, USP, 50 mg, 500-count bottles, Rx only, Manufactured by: Amneal Pharmaceuticals Pvt. Ltd., Ahmedabad 382220, India, Distributed by: Amneal Pharmaceuticals LLC, Glasgow, KY 42141, NDC 60219-2348-5.
Class II: Failed Impurities/Degradation Specifications: N-nitroso-desmethyl-tramadol impurity (NDSRI) was found out of the specification at 24-month s
Apr 7, 2026
earnings
Amneal to Report First Quarter 2026 Results on May 1, 2026
<p>BRIDGEWATER, N.J., April 07, 2026 (GLOBE NEWSWIRE) -- Amneal Pharmaceuticals, Inc. (NASDAQ: AMRX) (“Amneal” or the “Company”), today announced th
Apr 7, 2026
short_volume
Short Volume: AMRX — 72.0% short (0.4M / 0.5M)
Short: 390,189 | Exempt: 0 | TRF Vol: 541,942 | Short Ratio: 72.0% | Off-exchange volume (dark pool + OTC)
Mar 13, 2026
Clinical Trial
Study With CY, Pembrolizumab, GVAX Pancreas Vaccine, and SBRT in Patients With Locally Advanced Pancreatic Cancer
Phase Phase 2 — COMPLETED
Mar 5, 2026
other
Amneal to Participate in Upcoming Investor Conference
<p>BRIDGEWATER, N.J., March 05, 2026 (GLOBE NEWSWIRE) -- Amneal Pharmaceuticals, Inc. (Nasdaq: AMRX) today announced that Chirag Patel, Co-Chief Exe
Feb 27, 2026
earnings_calendar
AMRX Q4 2025 Earnings Before Market Open — 2026-02-27
Feb 20, 2026
Clinical Trial
Chemotherapy Based on PET Scan in Treating Patients With Stage I or Stage II Hodgkin Lymphoma
Phase Phase 2 — TERMINATED
Feb 20, 2026
Clinical Trial
S0125, Chemotherapy, Total-Body Irradiation, and Peripheral Stem Cell Transplantation in Treating Older Patients With Acute Myeloid Leukemia
Phase Phase 2 — TERMINATED